Plant Name: Scopolia japonica
Taxonomic Information:
Plant ID: NPO3890
Plant Latin Name: Scopolia japonica
Taxonomy Genus: Scopolia
Taxonomy Family: Solanaceae
Plant External Links:
NCBI TaxonomyDB:
221162
Plant-of-the-World-Online:
818000-1
Used in Medicines:
Country/Region:
South Korea; China; RomaniaTraditional Medicine System:
TCMMedicinal Functions:
Anodyne; Antispasmodic; Antitussive; Diuretic; Sedative
Geographical Distribution:
Japan; Romania; China; South Korea; South Africa
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CHRM2; CHRM1; DRD1; HTR6; CHRM5; CHRM3; | |
| TDP1; MTOR; | |
| CA12; CA9; | |
| MT-ND4; | |
| PMP22; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2D6; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | MT-ND4 | NADH-ubiquinone oxidoreductase chain 4 | P03905 | CHEMBL4499 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Unclassified | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 1.569E-12 | 1.708E-08 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 1.569E-12 | 1.708E-08 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 4.703E-12 | 3.414E-08 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 5.446E-09 | 7.411E-06 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 1.347E-06 | 1.174E-03 | CHRM1, CHRM3, CHRM5 |
| BP | GO:0032501; multicellular organismal process | GO:0007399; nervous system development | 4.831E-06 | 3.757E-03 | CHRM1, CHRM2, CHRM3, SMN1, SMN2 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 5.319E-06 | 3.994E-03 | CHRM1, CHRM2, CHRM3, DRD1, HTR6, MTOR, SMN1, SMN2 |
| BP | GO:0032501; multicellular organismal process | GO:0046541; saliva secretion | 6.423E-06 | 4.662E-03 | CHRM1, CHRM3 |
| CC | GO:0044456; synapse part | GO:0043679; axon terminus | 1.192E-05 | 8.370E-03 | CHRM1, CHRM2, CHRM3 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 3.633E-09 | 1.744E-07 | CHRM2, CHRM3, HTR6, CHRM1, CHRM5, DRD1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 4.766E-08 | 1.144E-06 | CHRM2, CHRM3, HTR6, CHRM1, CHRM5, DRD1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.553E-06 | 2.486E-05 | CHRM2, CHRM3, CHRM1, CHRM5 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.576E-05 | 1.891E-04 | CHRM2, HTR6, CHRM1, DRD1 |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 2.097E-05 | 2.013E-04 | CHRM2, CHRM3, CHRM1, CHRM5 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.103E-05 | 6.483E-04 | CA12, CA9 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; |
| NA: NA | Functional bowel syndrome | NA | CHRM1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2; |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR; CA9; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; CHRM5; HTR6; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6; |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MTOR; |
| NA: NA | Abdominal stomach pain | NA | CHRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; CHRM1; CHRM5; HTR6; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM3; CHRM5; |
| NA: NA | Schizoaffective disorders | NA | CHRM1; |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR; |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR; |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR; |
| NA: NA | Spasms | NA | CHRM3; |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3; |
| NA: NA | Addiction | NA | CHRM2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2; |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MTOR; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR6; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5; |
| NA: NA | Dystonia | NA | CHRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| NA: NA | Excessive sweating | NA | CHRM1; |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRM1; CHRM2; CHRM3; HTR6; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; CHRM1; HTR6; |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | CHRM2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; CHRM3; MTOR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MTOR; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | CHRM2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CHRM1; CHRM3; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRM2; |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | MTOR; CA9; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MTOR; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | MTOR; |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | CHRM1; CHRM3; CHRM5; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM5; |
| NA: NA | Coronary artery restenosis | NA | MTOR; |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; CHRM1; CHRM2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MTOR; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; CHRM1; CHRM5; HTR6; |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
